|
| Thursday, 24 January 2019, 10:27 HKT/SGT | |
| |  | |
Source: Fujitsu Ltd | |
|
|
|
TOKYO, Jan 24, 2019 - (JCN Newswire) - Fujitsu has enhanced its clinical trial-supporting Fujitsu Life Science Solution tsClinical DDworks21 series with the launch of the SaaS solution tsClinical DDworks21/Trial Site. The new solution, available from today, provides hospitals and other clinical trial sites in Japan with shared cloud-based control of documents conventionally exchanged in paper form between pharmaceutical companies developing new drugs and the sites conducting the clinical trials.
 | | Diagram of tsClinical DDworks21/Trial Site flow |
 | |
Clinical trial documents are records that prove a trial's reliability, so they are required by law to be stored long-term under strict control. Most clinical trial sites use paper records, and the exchange and storage of these documents remains labor intensive. After new drug approval, the documents must be managed properly for five years in Japan (in Europe, for a minimum of 25 years), a lengthy requirement that places a burden on hospital staff. The Trial Site solution reduces this operational burden and contributes to higher efficiency and lower costs. By adding this solution to the tsClinical DDworks21 series lineup, Fujitsu expands its business in the clinical trial field and contributes to the comprehensive optimization of clinical trials.
Background
New drug development is generally said to take 10 years and cost between 20 to 30 billion yen in Japan. In total, pharmaceutical companies in Japan spend 1.4 trillion yen annually on drug development, and lowering the cost of clinical trials represents a significant challenge.
In recent years, various industries are increasingly going paperless by digitizing documents. In the medical field, while pharmaceutical companies, particularly in new drug development processes, are transitioning toward digitization, most clinical trial sites still operate by affixing seal impressions on paper documents in clinical trials. As a result, the printing of enormous quantities of documents generated during clinical trials, filing tasks, and securing storage space remain a significant issue. For pharmaceutical company staff (monitors) who repeatedly visit clinical trial sites to deliver and receive paper documents and check on storage conditions, reducing the workload associated with clinical trials is an urgent issue.
To overcome these challenges, Fujitsu drew on its know-how in operational support for clinical trials gained through the development of the tsClinical DDworks21 series to create a new solution for clinical trial sites. At hospitals and other clinical trial sites, documents are managed as electronic originals on the cloud, and processes related to this management are streamlined and the quality is improved.
Prior to launching this solution, Fujitsu conducted a field trial with National Cancer Center Hospital East and National Cancer Center Hospital. The trial verified higher efficiency and proper control of digitized exchange and storage of clinical trial documents as well as Institutional Review Board (IRB) operations.
Main Features of the Solution
1. Reliable document management
When clinical trial documents are saved as part of the electronic exchange with pharmaceutical companies and during hospital workflow, they are managed by the automatic generation of appropriate folders based on meta data, such as the time and date they were created and the name of the trial. This enables reliable folder management and version number management for each study as well as easy access for the most recent data. Furthermore, paperless operations means the enormous volume of filing and storage space required at clinical trial sites is reduced, so costs go down.
2. Higher efficiency of clinical trial operations through a shared platform
Staff at clinical trial sites and pharmaceutical companies conducting clinical trials will use a specialized website to access data stored in a cloud environment, so operations previously handled manually at clinical trial sites by Clinical Research Coordinators (CRCs), such as printing and mailing paper documents, will be streamlined. This solution is also expected to reduce the workload of monitors from pharmaceutical companies associated with checking on document storage conditions at clinical trial sites. This will contribute to invigorating clinical trials in Japan and resolving issues affecting society, such as Japan's drug lag and device lag(1).
Comment from Dr. Toshihiko Doi, Deputy Director of National Cancer Center Hospital East
In this field trial, we successfully identified how to reduce operational burdens and increase efficiency for trial administrators by utilizing document digitization and systemized operation of process management. I hope this solution will be widely used by clinical trial sites and eventually link to tsClinical DDworks 21, which is used by many pharmaceutical companies. I have high expectations that Fujitsu will play a leading role as pharmaceutical companies and clinical trial sites share information on their respective needs and create a new platform.
Pricing and Availability
http://www.acnnewswire.com/topimg/Low_PricingtsClinicalDDworks21.jpg
(1) Drug lag and device lag The wait period of a pharmaceutical product or medical device approved overseas, before it is approved in Japan.
Contact:
Fujitsu Limited
Public and Investor Relations
Tel: +81-3-3215-5259
URL: www.fujitsu.com/global/news/contacts/
Topic: Press release summary
Source: Fujitsu Ltd
Sectors: Cloud & Enterprise
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Fujitsu Ltd |
| Feb 5, 2025 09:25 HKT/SGT |
|
Fujitsu to highlight AI-powered network technologies at MWC Barcelona 2025 |
| Feb 4, 2025 10:39 HKT/SGT |
|
Fujitsu launches gen AI software analysis and visualization service to support optimal modernization planning |
| Feb 3, 2025 11:05 HKT/SGT |
|
Fujitsu and Tokai National Higher Education and Research System leverage explainable AI to enhance space weather prediction in collaboration with JAXA |
| Jan 30, 2025 10:56 HKT/SGT |
|
Fujitsu and Asepeyo collaborate to modernise the management of occupational benefits and contingencies |
| Jan 27, 2025 09:53 HKT/SGT |
|
Sustainable Shared Transport and Fujitsu launch open platform for joint transportation and delivery in Japan, enhancing logistics efficiency across industries |
| Jan 15, 2025 12:13 HKT/SGT |
|
Fujitsu, Resona Bank and Saitama Resona Bank launch new web service to simplify home-buying process |
| Dec 23, 2024 12:30 HKT/SGT |
|
Fujitsu drives chemical industry logistics DX with participation in joint logistics demonstration |
| Dec 16, 2024 09:20 HKT/SGT |
|
Fujitsu recognized as Leader in IDC MarketScape: Worldwide Digital Workplace Services 2024 Vendor Assessment |
| Dec 12, 2024 10:06 HKT/SGT |
|
Fujitsu develops video analytics AI agent to support safe, secure, and efficient frontline workplaces |
| Dec 12, 2024 09:28 HKT/SGT |
|
Fujitsu develops world's first multi-AI agent security technology to protect against vulnerabilities and new threats |
| More news >> |
 |
|
|
|
